ArticleInflammatory bowel diseases2026

Persistence and safety of subcutaneous infliximab up to 1 year after switching from intravenous infliximab in pediatric inflammatory bowel disease: a multicenter real-world cohort study.

Esmée Helen Boute et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.